glp-1 myths Facts, Fiction, and Around GLP-1s Discussed at the ADA Scientific Sessions GLP-1 Medication Myths Debunked: Separating

These side effects are similar to those reported with other GLP-1 medications and are generally more common during dose escalation

This study included 3297 patients with T2D at high CV risk, 83% of whom had established CVD, chronic kidney disease (CKD), or both

For example, despite the enormous upsurge in the incidence of obesity and associated complications including T2DM (138), existing drug therapies for obesity are grossly insufficient, with bariatric surgery being far more effective (139)

New cases are being added steadily as more and more patients are experiencing the disadvantages of using GLP-1 drugs to lose weight

GLP-1 medications, or glucagon-like peptide-1 receptor agonists, mimic the bodys natural hormones to regulate glucose metabolism